Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 11/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.46 |
| ▸ | ALB | P02768 | 1/20 | 0.46 |
| ▸ | PGR | P06401 | 1/20 | 0.46 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.46 |
| ▸ | GHSR | Q92847 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30554602 | 1.00 | AR (0.49) | ARCYP2C19CYP2D6CYP2C9NR1H4 | |
| SCHEMBL30554617 | 0.87 | KDR (0.54) | NR1H4 | |
| SCHEMBL3246689 | 0.87 | KDR (0.54) | NR1H4 | |
| SCHEMBL17413358 | 0.86 | NR1H4 (0.50) | CYP2C19NR1H4 | |
| SCHEMBL2789070 | 0.84 | NR1H4 (0.41) | ARCYP2C19NR1H4ABCB11ALB | |
| SCHEMBL3248837 | 0.81 | AR (0.55) | ARCYP2C19CYP2C9NR1H4ABCB11 | |
| SCHEMBL30554582 | 0.81 | AR (0.55) | ARCYP2C19CYP2C9NR1H4ABCB11 | |
| SCHEMBL30554609 | 0.78 | P2RX1 (0.51) | — | |
| SCHEMBL3241964 | 0.78 | P2RX1 (0.51) | — | |
| SCHEMBL2787734 | 0.77 | NR1H4 (0.47) | CYP2C19CYP2C9NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | SILTI AG (CH) | 2024-02-29 | — | — | US | disclosed |
| EP-3164125-B1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | NAN GLOBAL LLC (US) | 2023-09-06 | — | — | EP | disclosed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | disclosed |
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2021-06-24 | — | — | US | disclosed |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | NAN Global, LLC (US) | 2020-12-01 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | MOLECULE X LLC | 2016-01-07 | — | — | US | disclosed |
| EP-1575575-B1 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | HIGH POINT PHARMACEUTICALS LLC (US) | 2010-05-19 | — | — | EP | disclosed |
| EP-1575575-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2005-09-21 | — | — | EP | disclosed |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | HIGH POINT PHARMACEUTICALS, LLC | 2004-07-15 | — | — | US | disclosed |
| WO-2004041256-A2 | SAFE CHEMICAL UNCOUPLERS FOR THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210186918-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | AR 2650/4885CYP2C19 3971/4885CYP2D6 4572/4885 |
| US-20240066001-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | AR 2650/4885CYP2C19 3971/4885CYP2D6 4572/4885 |
| US-20160000745-A1 | METHODS AND COMPOSITIONS FOR TREATING OBESITY, PREVENTING WEIGHT GAIN, PROMOTING WEIGHT LOSS, PROMOTING SLIMMING, OR TREATING OR PREVENTING THE DEVELOPMENT OF DIABETES | GPR119, CPT1B, CPT2 | AR 2650/4885CYP2C19 3971/4885CYP2D6 4572/4885 |
| US-20040138301-A1 | Chemical uncouplers for the treatment of obesity | PC, CPT2, IDH2 | AR 264/4885CYP2C19 882/4885CYP2D6 1293/4885 |
| US-10849872-B2 | Methods and compositions for treating obesity, preventing weight gain, promoting weight loss, promoting slimming, or treating or preventing the development of diabetes | GPR119, CPT1B, CPT2 | AR 2650/4885CYP2C19 3971/4885CYP2D6 4572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.